Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma -- Licensed SYN-020 to Rasayana Therapeutics ...
Yahoo Finance

Synthetic Biologics Completes Acquisition of VCN Biosciences

ROCKVILLE, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of ...
Cure Today

VCN-01 with Standard Care Boosts Survival, Shows Safety in PDAC

VCN-01 combined with standard therapy improved overall survival and progression-free survival in metastatic pancreatic ductal adenocarcinoma patients. The VIRAGE trial showed a 56% reduction in death ...
Yahoo Finance

Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American ...

ROCKVILLE, Md., May 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of ...
Nature

Oncolytic adenovirus VCN-01 turns cold tumors hot

Intriguing historical observations that some viral infections can promote cancer remission have led to investigations of the therapeutic potential of oncolytic viruses that replicate, infect and ...
PharmaTimes

Theriva Biologics reveals positive VCN-01 study results

The candidate is a stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer The candidate is a stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer Theriva ...